title: Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?
abstract: Bisphosphonates are recommended in the treatment of osteoporosis and some cancers, in which case they prevent the appearance of bone metastasis. The patients taking bisphosphonates are at increased risk of developing bisphosphonate-related osteonecrosis of jaw (BRONJ) which is characterised by the presence of an un-healing wound after dental surgery. BRONJ might represent an anti-angiogenic side effect. However, the real number of patients with BRONJ might be higher than currently recorded. Considering the differential diagnosis which includes various primary and secondary cancers, a correct histopathological diagnosis is very important. The morphological criteria for diagnosis of BRONJ are highlighted in this material.
authors: Griffith University School of Medicine, Gold Coast Campus, Griffith University, Griffith, QLD 4222, Australia. e_petcu@hotmail.com
authors: Eugen B
authors: EB
authors: Petcu
authors: Saso
authors: S
authors: Ivanovski
authors: Robert G
authors: RG
authors: Wright
authors: Mark
authors: M
authors: Slevin
authors: Rodica I
authors: RI
authors: Miroiu
authors: Klara
authors: K
authors: Brinzaniuc
mesh_terms: D015415:Biomarkers / Q000032:analysis; D001706:Biopsy; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000378:metabolism / Q000473:pathology*; D005147:Facial Bones / Q000098:blood supply / Q000737:chemistry / Q000473:pathology*; D006801:Humans; D018919:Neovascularization, Physiologic; D011237:Predictive Value of Tests; D014945:Wound Healing
chemical_list: D015415:Biomarkers